FDC
OVERVALUEDFDC Limited
Healthcare · NSE
↓ 123.2% vs fair value
52W Low
₹313
+18.5% from low
52W High
₹528
-29.7% from high
Valuation Gauge
Current Price
₹371
Fair Value
₹166
Fair Value Analysis
₹166
Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Healthcare sector companies
Cash Flow Analysis
40% weight
Balance Sheet Value
20% weight
Growth Valuation
40% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 9.8% is acceptable for Healthcare sector (benchmark: 15%)
Debt & Leverage
D/E ratio of 0.0x is well within the Healthcare sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 25.0x trades at a 84% discount to Healthcare sector median (160x) — attractively valued
Cash Flow
FCF margin of 10.5% — strong cash generation (₹221 Cr)
Earnings Growth
5yr EPS CAGR of 7.2% is well below Healthcare sector average of 18.7%
Dividend
Dividend yield of 2.7% provides strong shareholder returns (benchmark: 1.5%)
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
2.0%
Free cash flow / market cap
Revenue Growth (YoY)
-27.2%
Year-on-year revenue change
Profit Growth (YoY)
-58.1%
Year-on-year PAT change
Operating Cash Flow
₹318 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹14.6
P/E Ratio
25x
P/B Ratio
2.4x
ROE
9.8%
ROCE
15.4%
Debt / Equity
0.01x
Beta
0.15
Div Yield
2.7%
FCF (Cr)
₹221 Cr
Revenue (Cr)
₹2,108 Cr
EPS Growth 5Y
7.2%
Mkt Cap (Cr)
₹5,961 Cr
52W High
₹527.8
52W Low
₹313
Book Value/Share
₹151.1
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹2.1K Cr | ₹280 Cr | 13.0% | ₹217 Cr | ₹13.31 |
| 2025-03-31 | ₹2.1K Cr | ₹325 Cr | 15.0% | ₹267 Cr | ₹16.39 |
| 2024-03-31 | ₹1.9K Cr | ₹339 Cr | 17.0% | ₹305 Cr | ₹18.75 |
| 2023-03-31 | ₹1.8K Cr | ₹251 Cr | 14.0% | ₹194 Cr | ₹11.70 |
| 2022-03-31 | ₹1.5K Cr | ₹254 Cr | 17.0% | ₹216 Cr | ₹12.82 |
| 2021-03-31 | ₹1.3K Cr | ₹334 Cr | 25.0% | ₹301 Cr | ₹17.85 |
| 2020-03-31 | ₹1.3K Cr | ₹304 Cr | 23.0% | ₹240 Cr | ₹14.03 |
| 2019-03-31 | ₹1.1K Cr | ₹229 Cr | 21.0% | ₹170 Cr | ₹9.74 |
| 2018-03-31 | ₹1.1K Cr | ₹233 Cr | 22.0% | ₹174 Cr | ₹9.95 |
| 2017-03-31 | ₹1.0K Cr | ₹243 Cr | 24.0% | ₹189 Cr | ₹10.60 |
| 2016-03-31 | ₹994 Cr | ₹229 Cr | 23.0% | ₹169 Cr | ₹9.48 |
| 2015-03-31 | ₹888 Cr | ₹199 Cr | 22.0% | ₹148 Cr | ₹8.33 |
| 2014-03-31 | ₹845 Cr | ₹207 Cr | 24.0% | ₹135 Cr | ₹7.61 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Healthcare| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Anlon Healthcare Limited | ₹13.9 | ₹50.7 | +72.6% | 20.5 | 7.3% | UNDERVALUED |
Alpa Laboratories Limited | ₹69.8 | ₹196.4 | +64.5% | 12.8 | 13.4% | FAIRLY_VALUED |
Aster DM Healthcare | ₹755.4 | ₹1,585.8 | +52.4% | 117.6 | 7.9% | UNDERVALUED |
Vimta Labs Limited | ₹453 | ₹722.6 | +37.3% | 26.2 | 18.6% | UNDERVALUED |
Unichem Laboratories Limited | ₹372.6 | ₹592.5 | +37.1% | 8.9 | 12.1% | FAIRLY_VALUED |
Dishman Carbogen Amcis Limited | ₹195.5 | ₹281.2 | +30.5% | 25.6 | 1.9% | FAIRLY_VALUED |
Indraprastha Medical Corporation Limited | ₹358.2 | ₹462.6 | +22.6% | 18.5 | 20.6% | UNDERVALUED |
Morepen Laboratories Limited | ₹43 | ₹52.8 | +18.5% | 23.3 | 10.8% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant